Sino Biopharmaceutical (HKG:1177) unit's new drug application for M701 was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.
The drug was jointly developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of the firm, for the treatment of malignant ascites caused by advanced epithelial malignancies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.